EMA revises policies on handling competing interests

Article summary

The European Medicines Agency (EMA) has published revised policies on handling competing interests for scientific committee members, experts, and Management Board members. EMA has adopted these policies in December 2024, to be effective from May 2025. The revisions, particularly to Policy 0044, implement recent Court of Justice rulings and aim to ensure objective impartiality in EMA's assessments. The agency conducted a public consultation on the draft revised Policy 0044 and has published stakeholder comments and responses. These updates reflect EMA's commitment to maintaining a robust framework for managing competing interests whilst aligning with legal requirements.